Key statistics
On Friday, Zymeworks Inc (ZA8:DUS) closed at 11.60, -1.49% below its 52-week high of 11.78, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.50 |
---|---|
High | 11.60 |
Low | 11.40 |
Bid | 11.60 |
Offer | 11.90 |
Previous close | 11.30 |
Average volume | 194.80 |
---|---|
Shares outstanding | 71.05m |
Free float | 65.96m |
P/E (TTM) | -- |
Market cap | 930.01m USD |
EPS (TTM) | -1.52 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 18:30 BST.
More ▼
- Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
- Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
- Zymeworks Announces Participation in Upcoming Investor Conferences
- Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
- Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
- Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
- Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
- Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
- Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
More ▼